| Title: | Identification of precision therapeutics for Alzheimer's disease prevention and treatment |
| Lead Institution: | University of Arizona |
| Principal investigator: | Dr Francesca Vitali |
Application 72504
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
About
Over the course of the previous 20 years, Alzheimer's disease (AD) has become a major focus in biomedical and clinical research with major pharmaceutical and academic groups working towards clinical trials for both treatment and more recently prevention options for this devastating disease. Projections estimated that a 1-year delay in AD onset by 2020 would result in roughly 9 million fewer cases in 2050. Recent literature supports the targeting of biological mechanisms and pathways underlying AD risk factors has the potential to dramatically reduce global incidence of AD. Therapeutically targeting a risk factor is not the same strategy as targeting the disease itself. Thus single-target therapies effective in reducing risk of AD are not effective for treating AD. However, combination therapies tailored to the cascade of risk factors still hold potential. Detecting therapeutics that target a risk factor and reduce AD risk could provide a strategy for precision combination therapy to treat AD. Our precision medicine approach will generate scientific evidence needed to drive the development of therapies that treat the right person, with the right treatment at the right time. We propose the use of a precision medicine approach, which takes into account people's individual variations in genes, environment and lifestyle, for analysis of data from the UK BioBank.1 Publication
| Pub ID | Title | Author(s) | Year | Journal |
|---|---|---|---|---|
| 15392 | Multisystem failure, tipping points, and risk of Alzheimer's disease | Simona Merlini (+3) | 2025 | Alzheimer's & Dementia |
Enabling scientific discoveries that improve human health